Publication | Closed Access

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

S-1 MonotherapySurgical OncologyGastrointestinal OncologyMedicineBiliary CancerPathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchSecond-line Chemotherapy